Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge
- 445 Downloads
The objective of this project was to compare the time from initiation of oral anticoagulation to hospital discharge between warfarin and direct oral anticoagulants (DOACs) for the treatment of acute venous thromboembolism (VTE). This retrospective observational study was done at a single VA medical center. A total of 107 patients were included, with 42 patients (39%) in the DOAC group, which included rivaroxaban, dabigatran, and apixaban, and 65 patients (61%) in the warfarin group. Variables collected through chart review included comorbid conditions, time from initiation of oral anticoagulation to discharge, emergency department (ED) visits and readmission within 30 or 90 days, and bleeding events. The DOAC group had a shorter time to discharge compared to the warfarin group (28 vs. 114 h, p < 0.001). There were similar 30 and 90-day hospital readmission rates and/or ED visits for DOACs (23.8 and 33.3%) compared to warfarin (18.5 and 30.8%), including those related to bleeding of any severity (11.9% for DOACs vs. 9.2% for warfarin; p = 0.75). There was one major bleeding event in the DOAC group and two in the warfarin group. The use of DOACs for the treatment of acute VTE in hospitalized patients was associated with shorter time to hospital discharge when compared to warfarin.
KeywordsAnticoagulation Warfarin DOAC Venous thromboembolism Length of stay
This work was completed with support from the Central Texas Veterans Health Care System. The views expressed are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.
There was no source of funding for this study.
Compliance with ethical standards
Conflict of interest
Amanda N. Basto, Nathan P. Fewel, Kim Vo, Eileen M. Stock and Mia Ta declares that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
The local institutional review board waived the requirement of informed consent for this study.
- 4.Matsuo H, Prins M, Lesning AWA, Fujinuma EW, Miiyamoto Y, Kajikawa M (2015) Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program. Curr Med Res Opin 31(6):1057–1061CrossRefPubMedGoogle Scholar
- 8.Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, For the Subcommittee on Control of Anticoagulation (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119–2126CrossRefPubMedGoogle Scholar
- 9.Schulman S, Kearon C, The Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:392–694. doi: 10.1111/j.1538-7836.2005.01204.x Google Scholar